# Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

> clinical trial · VERIFIED · 2026-07-31

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Astrocytoma, IDH-Mutant, Grade 2

- Company: National Cancer Institute (NCI)
- Sector: Astrocytoma, IDH-Mutant, Grade 2
- Primary source: https://clinicaltrials.gov/study/NCT03528642

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.